<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218072</url>
  </required_header>
  <id_info>
    <org_study_id>HLX01-NHL01</org_study_id>
    <nct_id>NCT03218072</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas</brief_title>
  <official_title>A Phase Ia, Multi-centers, Open-label, Dose-escalation Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HLX01 (a Potential Rituximab Biosimilar) in Patients With CD20-positive B-cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <brief_summary>
    <textblock>
      To evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a potential
      rituximab biosimilar) in patients with CD20-positive B-cell lymphomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a phase Ia, multicenter, open-label, dose-escalation clinical study to evaluate the
      safety, tolerability, pharmacokinetics and pharmacodynamics characteristics of HLX01
      injection in patients with CD20-positive B-cell lymphomas.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2014</start_date>
  <completion_date type="Actual">January 31, 2015</completion_date>
  <primary_completion_date type="Actual">January 31, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs</measure>
    <time_frame>From First infusion to Day 90</time_frame>
    <description>The type, severity and incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAEs</measure>
    <time_frame>From First infusion to Day 90</time_frame>
    <description>Thetype, severity and incidence of SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>From First administration to Day 90</time_frame>
    <description>Area under the serum concentration-time curve from time 0 extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>From First administration to Day 90</time_frame>
    <description>Maximum serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>From First administration to Day 90</time_frame>
    <description>terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD19 positive B cells</measure>
    <time_frame>From First administration to Day 90</time_frame>
    <description>The count of CD19 positive in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD20 positive B cells</measure>
    <time_frame>From First administration to Day 90</time_frame>
    <description>The count of CD20 positive in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies of HLX01</measure>
    <time_frame>From First administration to Day 90</time_frame>
    <description>The concentration of anti-HLX01 in serum</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>B-cell Lymphomas</condition>
  <arm_group>
    <arm_group_label>HLX01 250 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX01 250 mg/m2 administrated intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLX01 375 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX01 375 mg/m2 administrated intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLX01 500 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX01 500 mg/m2 administrated intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX01</intervention_name>
    <description>a potential rituximab biosimilar</description>
    <arm_group_label>HLX01 250 mg/m2</arm_group_label>
    <arm_group_label>HLX01 375 mg/m2</arm_group_label>
    <arm_group_label>HLX01 500 mg/m2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years ≤ aged ≤ 65 years, male or female;

          -  having histologically confirmed diagnosis of relapsed/refractory CD20-positive B-cell
             lymphomas which needed consolidation therapy;

          -  Eastern Cooperative Oncology Group (ECOG) performance status≤1 and life expectancy ≥3
             months;

          -  providing signed and dated informed consents.

        Exclusion Criteria:

          -  Usage of rituximab or other anti-CD20 monoclonal antibody within 2 years before
             enrollment;

          -  usage of hematopoietic cytokines within 1 week before enrollment, e.g. granulocyte
             colony stimulating factor (G-CSF);

          -  recent major surgery (excluding diagnostic surgery) within the past 8 weeks;

          -  peripheral nervous system diseases or central nervous system diseases;

          -  inadequate hematologic function met any of the following at screening: white blood
             cell count &lt;3.0×109/L, absolute neutrophil count (lobocyte and rhabdocyte) &lt;1.5×109/L,
             platelet count &lt;100×109/L, hemoglobin &lt;90 g/L, for patients with bone marrow
             involvement, absolute neutrophil count (lobocyte and rhabdocyte) &lt;1.0×109/L, platelet
             count &lt;75×109/L, hemoglobin &lt;80 g/L;

          -  inadequate liver function met any of the following at screening: total
             bilirubin&gt;1.5×the upper limit of normal range (ULN), ALT or AST&gt;2.0×ULN, alkaline
             phosphatase (ALP)&gt;3.0×ULN;

          -  abnormal renal function (serum creatinine&gt;1.5×ULN);

          -  abnormal thyroid function (TSH&lt; lower limit of normal or &gt; upper limit of normal with
             clinical significance judged by investigators);

          -  positive test result(s) for serum HIV antigen or antibody;

          -  seropositivity of HBsAg, or seropositivity of HBcAb and HBV DNA&gt;ULN; seropositivity of
             Anti HCV antibody;

          -  history of herpes zoster and left with sequelae or latent infection;

          -  other serious disease which may restrict subjects to participate in the trial (such as
             ongoing active infection, uncontrolled diabetes mellitus, severe cardiac insufficiency
             or angina pectoris, gastric ulcer, active autoimmune disease, etc.);

          -  pregnancy or breast feeding female, or not willing to use effective contraceptive
             measures during the study;

          -  allergic constitution, or known allergic to components of rituximab or other anti-CD20
             monoclonal antibody;

          -  history of alcoholism or drug abuse; participation in other clinical trials within 3
             months before enrollment;

          -  not suitable for enrollment at investigator's discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

